Exact Sciences (EXAS) Statistics

Exact Sciences Corp (EXAS) is a leading healthcare company that specializes in the development and commercialization of molecular diagnostic tests for the early detection and prevention of colorectal cancer. As of the last reported period, the stock statistics for EXAS are as follows: the stock price is $110.45, with a market capitalization of $17.96 billion. The stock has a 52-week range of $32.94 to $164.13, with a beta of 1.52, indicating above-average volatility compared to the market. The average trading volume for EXAS is around 1.34 million shares. In terms of valuation metrics, the price-to-earnings ratio (P/E) for EXAS is 195.99, highlighting the growth potential and high investor expectations for the company. The price-to-sales ratio (P/S) for EXAS is 25.65, indicating that investors are willing to pay a premium for the company's revenue. The price-to-book ratio (P/B) is 20.91, reflecting the market's confidence in EXAS's asset value. According to the fundamentals, EXAS has a return on equity (ROE) of -26.14%, suggesting that the company's profitability is currently under pressure. The return on assets (ROA) is -18.14%, further highlighting the challenges faced by EXAS in generating profits. In terms of stock performance compared to its sector, EXAS has outperformed the S&P 500 healthcare sector index by 48.7% in the past year. This demonstrates the company's ability to deliver superior returns to its investors. The revenue per share for EXAS is $14.29, signaling the company's strong top-line growth. However, it is important to note that revenue per share can be influenced by factors such as stock splits. The enterprise value to earnings before interest, taxes, depreciation, and amortization (EBITDA) ratio for EXAS is 260.9, suggesting that the company is trading at a premium relative to its EBITDA. The profit margin for EXAS is currently -38.63%, indicating that the company is currently operating at a loss. This is a concern for investors as it raises questions about the sustainability of the business model. As of the last reported period, EXAS has total debt of $1.38 billion. This includes both short-term and long-term debt obligations, which highlights the company's reliance on borrowed funds for its activities. The gross profit for EXAS is $1.06 billion, indicating the company's ability to generate profits after accounting for the cost of goods sold. In conclusion, Exact Sciences Corp (EXAS) is a healthcare company with promising growth potential. However, it faces challenges in terms of profitability and debt obligations. Investors should carefully evaluate these factors before making investment decisions.

Kevin T. Conroy is the CEO of Exact Sciences Corp (EXAS). He has been with the company since its founding in 1995 and has played a crucial role in its growth and success. Conroy is a seasoned executive with extensive experience in the healthcare industry. Under his leadership, Exact Sciences has become a leading player in the field of molecular diagnostic tests for the early detection and prevention of colorectal cancer. Conroy is known for his strategic vision and ability to drive innovation. He has successfully led the development and commercialization of Cologuard, Exact Sciences' flagship product, which has revolutionized the way colorectal cancer is screened. Prior to joining Exact Sciences, Conroy held various executive positions at Third Wave Technologies, a molecular diagnostics company. He holds a Bachelor of Arts degree in economics from Boston College and a Master of Business Administration degree from Harvard Business School. As the CEO of Exact Sciences, Conroy is responsible for setting and executing the company's strategic direction, overseeing operations, and driving growth. He is known for his hands-on approach and his strong commitment to improving patient outcomes. With his expertise and leadership, Conroy has positioned Exact Sciences as a leading force in the fight against colorectal cancer.